Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study.

Federico PirroGiacomo CaldarolaAndrea ChiricozziMartina BurlandoMarco MarianiAurora ParodiKetty PerisClara De Simone

Published in: Clinical drug investigation (2021)

Obesity (BMI ≥ 30 kg/m2) negatively affects the clinical response of biological drugs in psoriatic patients, with anti-interleukin drugs being more affected by BMI than anti-tumor necrosis factor drugs.

Keyphrases

body mass index
weight gain
rheumatoid arthritis
metabolic syndrome
insulin resistance
physical activity
weight loss
drug induced
ankylosing spondylitis
disease activity
skeletal muscle
systemic lupus erythematosus
high fat diet induced